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Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal
osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of
syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediator of
osteoblastic activity and bone formation, provided the platform for the evaluation of inhibitors of scle-
rostin to activate bone formation. An extensive preclinical program and 2 large fracture endpoint trials
with romosozumab, a sclerostin-binding antibody, have been completed. This review will highlight the
results of those studies and describe the current status of romosozumab as a potential therapy for
osteoporosis.
© 2018 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteoporosis is a disorder of increased fracture risk character-
ized by low bone mass and microarchitectural deterioration of the
trabecular and cortical skeletal envelopes [1]. To restore the
damaged and disconnected trabecular architecture will require
strategies to stimulate new bone formation. The most commonly
used treatments for osteoporosis, however, are antiremodeling
drugs that decrease bone formation as well as bone resorption,
precluding their ability to restore skeletal architecture or to cure
osteoporosis. Parathyroid hormone analogues do increase bone
formation but also activate bone resorption, limiting the anabolic or
bone forming response.
The discovery of sclerostin as a key inhibitor of bone formation
was made by groups evaluating patients with 2 rare autosomal
recessive syndromes associated with high bone mass [2]. Sclero-
stiosis is a disorder characterized by very high bone mass due to
inactivating mutations of the SOST gene on chromosome 17q21, the
gene that codes for sclerostin. Excess bone growth during child-
hood results in frontal bossing, cranial and basilar stenosis, cranial
nerve entrapment, and mandibular hypertrophy. Patients with Van
Buchem disease, a somewhat less severe disorder, have a separated Road, Portland, OR, 97210,
ociety of Osteoporosis.
osis. Publishing services by Elsevnoncoding deletion of a gene required for normal transcription of
the SOST gene. Heterozygous cases of both disorders have moder-
ately high bone mass without other phenotypic or clinical features.
Sclerostin is most highly expressed in osteocytes. Binding of scle-
rostin to low-density lipoprotein receptor-related proteins 5 and 6
(LRP5 and LRP6) prevents activation of canonical Wnt signaling in
bone, resulting in decreased bone formation. These findings stim-
ulated interest in exploring the potential of antisclerostin therapy
as a strategy to increase bone formation and to restore skeletal
architecture in patients with osteoporosis.
2. Preclinical studies
Genetic deficiency of sclerostin in rodents is associated with
high bone mass, increased bone formation in both trabecular and
cortical bone, normal bone quality and increased bone strength,
recapitulating the high bone mass syndrome of sclerostiosis [3].
The mineralization of the bone matrix in sclerostin-deficient ani-
mals is normal or reduced, accounting for the lack of bone brit-
tleness seen in patients with osteopetrosis due to osteoclast
deficiency or dysfunction.
Inhibition of sclerostin by monoclonal antibodies in rats and
monkeys resulted in robust anabolic responses on trabecular,
endocortical, intracortical and periosteal bone surfaces [4]. In aged,
ovariectomized rats, antisclerostin therapy increased trabecular
and cortical bone thickness and reduced cortical porosity. After 5
weeks of treatment, the skeletal abnormalities induced by ovari-
ectomywere corrected, and bonemass and bone strength exceededier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Comparison of changes in areal and volumetric BMD and in estimated bone strength
over 12 months of therapy with romosozumab and teriparatide.
Reference Romosozumab 210mg QM Teriparatide 20 mg/d
Areal BMD (DXA)
Lumbar spine [12] 12.3%a 6.9%
Total hip 3.9%a 0.8%
Integral volumetric BMD (QCT)
Lumbar spine [12] 17.7%a 12.9%
Total hip 4.1%a 1.2%
Estimated bone strength (FEA by QCT)
Lumbar spine [13] 27.3%a 18.5%
Total hip 3.6%a 0.7%
BMD, bone mineral density; QM, once monthly; DXA, dual-energy X-ray absorpti-
ometry; QCT, quantitative computed tomography; FEA, finite element analysis.
a p 0.05 vs. teriparatide.
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omolgus monkeys, treatment with a humanized antisclerostin
antibody for 2 months transiently increased markers of bone for-
mation and induced anabolic responses on all skeletal surfaces.
Bonemineral density (BMD) in the lumbar spine (LS), femoral neck,
proximal tibia, and distal radius increased significantly, correlated
with a substantial increase in LS and femoral diaphyseal bone
strength [5].
The skeletal response to antisclerostin therapy in old mice was
similar to that observed in younger animals, important since
osteoporosis is primarily a disorder of older men and women [4].
The anabolic response to antisclerostin therapy was restored upon
retreatment following a short treatment free interval. Following
antisclerostin therapy with an inhibitor of RANK ligand, a potent
antiremodeling agent, preserved or amplified the gain in bonemass
achieved with the antisclerostin therapy. The skeletal response to
antisclerostin therapy was not blunted in animals pre-treated with
bisphosphonates.
3. Clinical studies
Single and multiple dose phase 1 studies (ClinicalTrials.gov
Identifiers: NCT01059435 and NCT01825785) with romosozumab
(originally known as AMG 785/CDP7851) in healthy men and
women demonstrated a brisk increase in biochemical indices of
bone formation accompanied by a decrease in markers of bone
resorption [6,7]. These divergent effects of romosozumab on bone
formation and bone resorption are very distinct from the re-
ductions in both resorption and formation by antiremodeling
agents and the increases in both components of the remodeling
cycle by teriparatide and abaloparatide [8]. BMD values, measured
by dual-energy X-ray absorptiometry in the LS and total hip (TH),
increased by 5.2% and 1.1%, respectively, when measured 85 days
after the single-dose. Similar results were observed in the
ascending multiple dose study [6]. Romosozumab was adminis-
tered by subcutaneous (SQ) injections of 1 or 2mg/kg every 2
weeks (Q2W) or 2 or 3mg/kg every 4 weeks for 3 months. The
biochemical marker responses to the injections were maintained
during the first 2 months of dosing but were somewhat blunted
following the final dose compared to the initial dose. Pharmaco-
kinetics of romosozumab were similar in men and women.
In a placebo-controlled phase 1b study (ClinicalTrials.gov
Identifier: NCT01825785), the effects of romosozumab on volu-
metric BMD (vBMD) and bone structure were assessed by high
resolution quantitative computed tomography (HR-QCT) scans of
the LS in 48 subjects (32 women, 16 men) with low bone mass who
received active treatment with doses ranging from 1e3mg/kg Q2W
for 3months, followed by no therapy for an additional 3months [9].
At 3 months, HR-QCT assessments of trabecular BMD and stiffness
increased by 9.5% and 26.9%, respectively, and were significantly
greater than the changes in the placebo group (3.0% and 2.7%,
respectively). These improvements were maintained during the 3-
month off-treatment follow-up period.
An international phase 2 dose-ranging study (ClinicalTrials.gov
Identifier: NCT00896532) assessed responses to romosozumab
treatment in 419 postmenopausal womenwith low bonemass [10].
The patients, ages 55e85, were randomly assigned to receive
monthly SQ doses of romosozumab (70, 140, or 210mg) or doses of
140mg or 210mg every 3 months, or placebo injections [10]. Other
patients were randomly assigned to receive open label alendronate
70mg once weekly (QW) or teriparatide 20 mg SQ daily. As seen in
the phase 1 studies, romosozumab therapy resulted in rapid and
substantial increases in serum bone formation markers (serum
P1NP and alkaline phosphatase [AP]) but a decrease in the bone
resorption marker serum b-CTX. Serum P1NP values peaked at 4weeks, returned to baseline between 3 and 6 months and were
below baseline for the remainder of the treatment interval. All
doses of romosozumab increased BMD at both the spine and
proximal femur. The largest increases at 12 months were observed
with romosozumab 210mg once monthly (QM), the dose chosen
for phase 3 studies. BMD in the LS and TH had increased by 11.3%
and 4.1%, respectively, and these gains were significantly greater
than with teriparatide or alendronate. During the second year of
the study, markers of bone formation and resorption remained
below baseline in women who continued romosozumab (McClung
MR et al. J Bone Miner Res, 2014;29[Supp. 1] oral presentation
1152). Consistent with the lack of anabolic effect demonstrated by
bone markers during the second year of romosozumab therapy,
smaller increases in BMD occurred than had been observed during
the first year. After 2 years, romosozumab therapy was dis-
continued. In patients randomly switched to placebo for 12months,
BMD values in the spine and hip returned to or toward baseline
values. Serum b-CTX values rose above baseline before returning
toward pretreatment values while markers of bone formation
gradually returned to baseline values. In patients who were
switched to denosumab 60mg SQ every 6 months (Q6M), BMD
increased in a fashion similar to the increases during the second
year of romosozumab therapy.
In a similar phase 2 study, 252 postmenopausal Japanese
women with osteoporosis received romosozumab in doses of 70,
140, and 210mg QM or placebo (ClinicalTrials.gov Identifier:
NCT01101061) [11]. All doses resulted in significant gains in BMD at
the LS and proximal femur compared to baseline and to placebo. At
12 months with the 210mg QM dose, the average gains were 16.9%
and 4.7% in the LS and TH, respectively. Changes in serum markers
of bone turnover were similar to those observed in the interna-
tional phase 2 study.
In a subset of patients from the international phase 2 study,
areal and vBMD of the LS and TH was assessed by quantitative
computed tomography (QCT) in patients who received placebo
(n¼ 27), teriparatide 20 mg daily (n¼ 31) or romosozumab 210mg
QM (n¼ 24) for 12months [12] (Table 1). DXA BMD increased 12.3%
in the LS and 3.9% in TH with romosozumab compared to 6.9% and
0.8%, respectively, with teriparatide. Gains in both vBMD and esti-
mated strength, assessed by finite element analysis, of the hip and
spine were significantly greater with romosozumab than with
teriparatide [13]. The skeletal effects of romosozumab have also
been compared with teriparatide in a randomized but open label
phase 3 study (ClinicalTrials.gov Identifier: NCT01796301) in 436
postmenopausal women with osteoporosis who had previously
taken bisphosphonates for at least three years (mean duration
5.6 years) [14]. After 12 months of therapy, TH areal BMD by DXA
increased by 2.6% (95% confidence interval [CI], 2.2e3.0) in the
M.R. McClung / Osteoporosis and Sarcopenia 4 (2018) 11e15 13romosozumab groupwhile a decrease by 0.6% (95% CI,1.0 to0.2)
was observed in the women who received teriparatide. Integral
vBMD of the hip, based on QCT analysis, increased more in the
romosozumab group, while trabecular vBMD increased similarly in
both treatment groups. The decrease in cortical vBMD of the hip
observed with teriparatide (3.6%) was not observed with romo-
sozumab (þ1.1%). QCT-derived estimates of hip bone strength
increased significantly more with romosozumab at 12 months
(2.5%) than with teriparatide (0.7%).
Two phase 3 studies have evaluated the effects of romosozumab
on fracture risk reduction. The Fracture Study in Postmenopausal
Women with Osteoporosis (FRAME) (ClinicalTrials.gov Identifier:
NCT01575834) is an international, randomized, double blind study
of 7180 women, average age 71 years, who received either romo-
sozumab 210mg QM or placebo for 12 months followed then by an
additional 12 months of open label therapy with denosumab 60mg
Q6M in both treatment groups [15]. During the first 12 months of
therapy, romosozumab reduced the incidence of new vertebral
fractures by 73% (0.5% vs. 1.8% with placebo). Among those women
with spinal x-rays available for analysis, vertebral fractures
occurred in 16 of 3321 patients in the romosozumab group and in
59 of 3322 patients in the placebo group. Romosozumab therapy
significantly reduced clinical fracture risk by 36% at 12 months and
nonvertebral fracture risk by 25% compared to placebo, but the
reduction in non-vertebral fractures was not statistically significant
(adjusted p¼ 0.10).
There was a difference in nonvertebral fracture response ac-
cording to the location of the study sites. In a preplanned subgroup
analysis, a significant interaction of nonvertebral fracture risk
reduction with geography was observed [15]. In Latin American
study sites, the risk of nonvertebral fracture was much lower than
in other parts of theworld, and therewas no effect of romosozumab
therapy on nonvertebral fracture risk. In a post hoc analysis, non-
vertebral fracture risk was significantly reduced after 12 months of
therapy by 42% in all study sites after excluding those from Latin
America. During the year of open label denosumab therapy, 80%
fewer women who had received romosozumab (5) during year 1
had vertebral fractures than in the group who had taken placebo
(25) during the first year.
The Active-Controlled Fracture Study in Postmenopausal
Women with Osteoporosis at High Risk (ARCH) (ClinicalTrials.gov
Identifier: NCT01631214) compared the effects of SQ romosozu-
mab 210mg QM with oral alendronate 70mg QW for 12 months,
followed by open label alendronate therapy in both treatment
groups for up to an additional 2 years [16]. A total of 4093 women
were enrolled in the study. These women were selected to be at
much higher risk of fracture than were the women in the placebo-
controlled FRAME study. There were two sets of entry criteria for
ARCH: (1) a BMD T-score of 2.5 or less at the TH or femoral neck
and either one or more moderate or severe vertebral fractures or
two or more mild vertebral fractures; or (2) a bone mineral density
T-score of 2.0 or less at the TH or femoral neck and either two or
more moderate or severe vertebral fractures or a fracture of the
proximal femur that had occurred 3e24 months before randomi-
zation. The average age of the study participants was 74.3 years,
and more than half of the womenwere age 75 or older. The average
T-score values in the LS and THwere2.96 and2.80, respectively.
Ninety-nine percent of the women had a history of a fragility
fracture since age 45, including 96.1% of women with an adjudi-
cated vertebral fracture at baseline. The primary endpoints of the
study were the reduction in vertebral fracture incidence at 12 and
24 months and the cumulative incidence of clinical fractures
(nonvertebral and symptomatic vertebral fracture) at the time of
the primary analysis (when clinical fracture had been confirmed in
at least 330 patients and all the patients had completed the month24 visits). Secondary endpoints included nonvertebral and hip
fracture risk reduction at the primary analysis.
After 12 months of therapy, new vertebral fractures occurred in
4.0% of the women who received romosozumab and in 6.1% of
alendronate-treated women, resulting in a relative reduction in
vertebral fracture risk, compared to alendronate, of 37% (p¼ 0.003).
Clinical fracture risk was reduced by 28% (hazard ratio [HR], 0.72;
95% CI, 0.54e0.96) with romosozumab compared to alendronate.
Similarly, nonvertebral fracture risk was 26% lower with romoso-
zumab at 12 months, but this did not quite achieve statistical sig-
nificance (p¼ 0.06). BMD at the LS increased by 13.7% after 12
months of romosozumab treatment compared to 5.0% with
alendronate. Likewise, the increase in TH BMD was greater with
romosozumab (6.2%) vs. alendronate (2.8%).
The benefit of romosozumab on vertebral fracture risk
continued during the second year of the study during which all
women received alendronate therapy. Compared to the group that
received alendronate during year 1, vertebral fracture risk was 48%
lower (6.2% vs. 11.9%) in the women who had taken romosozumab.
During that second year, 45 women who had taken romosozumab
had new vertebral fractures while receiving alendronate vs. 115
womenwho took alendronate in both years 1 and 2. BMD increased
similarly in both treatment groups during year 2, with total in-
creases over 2 years of 15.2% and 7.1% in the LS and TH, respectively,
in women who received romosozumab followed by alendronate.
In the primary analysis, clinical fracture risk was reduced by 27%
(9.7% vs. 13.0%; HR, 0.73; 95% CI, 0.61e0.88; p< 0.001) with
romosozumab followed by alendronate (9.7%) compared to
alendronate alone (13.0%). Additionally, in the romosozumab-
alendronate group, nonvertebral fracture risk was significantly
reduced by 19% (p¼ 0.04) as was hip fracture risk (38% lower,
p¼ 0.02).
4. Safety
In the clinical trials, romosozumab has beenwell tolerated. Mild
injection site reactions were reported in 4.4%e5.2% of participants
receiving romosozumab 210mg QM vs. 2.6%e2.9% of controls
[15,16]. One patient in a phase 1 romosozumab study developed
transient, symptomatic elevation of serum transaminase [7], but
alterations in liver function have not been generally observed with
romosozumab therapy. Mild, transient and asymptomatic re-
ductions in serum calciumwith the expected reciprocal increases in
PTH occurred infrequently with the higher doses in the phase 2
study [10]. Patients with vitamin D deficiency were excluded from
the FRAME and ARCH studies, and a loading dose of 50,000 to
60,000 IU of vitamin D was given at the beginning of the trial to
participants whose baseline serum 25-hydroxyvitamin D level was
40 ng per mL or lower [15,16]. In addition, all women received daily
supplements of calcium (500e1000mg) and vitamin D (600e800
IU) during the studies. In FRAME, the average serum calcium
decreased by 2% after 1 month of romosozumab therapy, and 1
subject who received romosozumab in both FRAME and ARCH
developed asymptomatic hypocalcemia.
Anti-romosozumab antibodies have been detected in 15%e20%
of patients during the first year of therapy, including about 3% of
patients whose antibodies had neutralizing activity in vitro
[10,15,16]. However, there was no evidence that these antibodies
altered the efficacy or safety of therapy, and neither the presence
nor titer of antibodies correlated with injection site reactions or
other adverse events.
Because cellular proliferation in many tissues is governed by
canonical Wnt signaling, theoretical concern existed about the
possibility of inducing malignancy with antisclerostin therapy [17].
No treatment related effects on tumor incidence was observed in a
Fig. 1. Percent changes from baseline at 24 months (M) in bone mineral density (BMD)
of the lumbar spine and total hip in postmenopausal women with osteoporosis with
various treatment regimens. 1, alendronate (ALN) [16]; 2, zoledronic acid (ZOL) [24]; 3,
denosumab (DMab) [25]; 4, teriparatide (TPTD) [25]; 5, denosumab plus teriparatide
[25]; 6, romosozumab 12M and alendronate 12M [16]; 7, romosozumab 12M and
denosumab 12M [15].
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differ from the dose-dependent induction of osteosarcoma in
similar rat toxicity studies with other anabolic therapies teripara-
tide and abaloparatide [19,20].
No important vascular safety signals with romosozumab were
noted in FRAME [15]. Adjudicated cardiovascular events occurred in
1.1% of women receiving placebo and in 1.2% of those who took
romosozumab. Deaths occurred in 0.8% of the romosozumab
groups and in 0.6% of women receiving placebo. In ARCH, however,
after 12 months of therapy, adjudicated cardiovascular events and
stroke were reported more often with romosozumab (0.8% for
both) than with alendronate (0.3% for both adverse events) [16].
Thirty of the 2040 women (1.5%) in the romosozumab group died
during the first year of ARCH compared to 21 of 2014 women (1.0%)
taking alendronate. The 0.5% difference in mortality persisted
throughout follow-up period while all patents were taking
alendronate.
The mechanism of the possible adverse vascular effect of
romosozumab is not known. Any explanation would have to ac-
count for the disparity of results between the placebo controlled
study (FRAME) and the active comparator study (ARCH). AP activity
in vascular smooth muscle cells is a marker of vascular calcification
[21], and bone AP is transiently stimulated by romosozumab ther-
apy. Sclerostin is up-regulated during vascular calcification in vitro,
but whether this is a cause of or response to the calcification is not
known [22,23]. Additional analyses of the results from FRAME and
ARCH, including comparisons of the different patient populations,
will hopefully shed light on the underlying mechanism and clinical
relevance of the cardiovascular findings in ARCH.
5. Current status
The results of FRAME formed the basis of the recent filing with
regulatory agencies for registration of romosozumab as a treatment
for postmenopausal osteoporosis. That application is pending re-
view in Europe. In the United States, the original application was
withdrawn, and a new application that includes both the efficacy
and safety data from ARCH is being submitted. Meanwhile, follow-
up of women in the FRAME and ARCH studies is on-going. Addi-
tional information will be available from the international phase 2
study including the effects of retreatment with romosozumab.
Results will be available soon from small studies evaluating the
BMD and turnover responses to romosozumab in men with oste-
oporosis (ClinicalTrials.gov Identifier: NCT02186171) and in Korean
women with postmenopausal osteoporosis (ClinicalTrials.gov
Identifier: NCT02791516).
6. Commentary
The discovery of sclerostin was quickly recognized as an op-
portunity to develop a unique new therapy for osteoporosis that, by
blocking sclerostin action, would activate bone formation while
reducing bone resorption. That possibility grew in likelihood as the
clinical features of sclerostin deficiency syndromes were explored
and by the ability of anti-sclerostin therapy to normalize bonemass
and strength in animals. Most of the promise of that idea has been
realized with romosozumab followed by an anti-remodeling drug.
That strategy effectively reduces the risk of important fractures and
produces faster and greater increases in BMD and bone strength
than with any current osteoporosis treatment [15,16,24,25] (Fig. 1).
However, in addition to concerns about possible vascular side ef-
fects, there are limitations to the promise of romosozumab as a
possible “cure” for osteoporosis. Monthly dosing, administered by
health professionals, will be inconvenient. More importantly, the
robust anabolic effect of treatment is limited to the first fewmonths of therapy, curtailing the progressive, large increases in
bone mass. Perhaps a strategy can be identified whereby patients
can experience the anabolic effects of romosozumab on multiple
occasions with a limited interval or the use of alternate drugs be-
tween courses. Romosozumab is very effective in treatment-naïve
patients, but, although not directly compared in head-to-head
studies, the BMD response to therapy appears to be more modest
in patients who have taken bisphosphonates [14].
These limitations, though, do not detract from the impressive
effectiveness of fracture risk reduction with romosozumab. While
the relative reduction in vertebral fracture risk during the first year
of therapy in FRAME was similar (61%) to that observed with other
osteoporosis drugs, FRAME was the first study to demonstrate that
beginning treatment with an anabolic agent, followed by a potent
antiremodeling drug, was more effective than starting with anti-
remodeling therapy. An 80% greater reduction in vertebral fracture
risk was observed during year 2 of FRAME in patients who received
romosozumab followed by denosumab compared to the placebo-
denosumab group [15].
In ARCH, the effects of romosozumab were clearly superior to
alendronate therapy, the most extensively studied and most
commonly used osteoporosis drug [16]. Furthermore, the 48%
greater reduction in vertebral fractures during year 2 in the
romosozumab-alendronate group confirmed the superiority of
using an anabolic agent followed by an antiremodeling drug
compared to starting with antiremodeling therapy.
The results of FRAME and ARCH should convince clinicians and
payers that beginning treatment with an anabolic agent in patients
at very high or imminent risk of fracture is the most effective and
the appropriate treatment plan, especially since romosozumab-
would be used for only 12 months.
Hopefully, the question of cardiovascular safety will not derail
registration and availability of romosozumab for the treatment of
women with postmenopausal osteoporosis at high-risk of fracture.
If approved, there should be few cautions or contraindications
other than pregnancy and hypersensitivity. Hypocalcemia is an
expected response to the first dose of romosozumab because of the
inhibition of bone resorption combined with the mineralization of
the large amount of new bone matrix formed by treatment. It is my
opinion that patients with hypocalcemia or vitamin D deficiency
should not be treated with romosozumab, that adequate intakes of
calcium and vitamin D should be ensured before treatment is
begun, and that serum calcium should be monitored after initial
M.R. McClung / Osteoporosis and Sarcopenia 4 (2018) 11e15 15dosing in patients at risk for hypocalcemia. It would also be wise to
avoid therapy in patients with or at risk of skeletal metastases or
with other high bone remodeling conditions such as Paget disease
of bone.
Beyond the use of romosozumab to treat postmenopausal and
age-related osteoporosis, it is appealing to consider the use of this
the unique anabolic response to romosozumab therapy in several
states of low bone turnover including idiopathic osteoporosis in
young adults, anorexia nervosa, adynamic renal osteodystrophy
and glucocorticoid-induced osteoporosis. Studying the effects of
antisclerostin therapy in those conditions will be very interesting.
7. Conclusions
Romosozumab is an exciting potential therapy for osteoporosis,
and, if approved, its availability will usher in a new era of osteo-
porosis therapy.
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